A unique monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – shows considerable promise for the treatment of critical transfusion-related condition (TRALI). Engineered by Bio-X, Pritoxaximab https://www.targetmol.com/compound/pritoxaximab